Overview

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb